Merus Labs International Inc.

Merus Labs International Inc. was a specialty pharmaceutical company focused on the acquisition, optimization, and licensing of established legacy and growth medicines. Headquartered in Toronto, Canada, the company built a scalable commercial platform that served critical treatment categories across Europe, North America, and selected global markets. The firm specialized in acquiring stable, market-proven product lines from tier-one manufacturers and introducing targeted re-launch marketing programs to maximize patient access and brand equity.

Corporate operations as a standalone issuer concluded following a definitive plan of arrangement that resulted in the company’s acquisition by Amsterdam-based Norgine B.V. This transaction integrated Merus’s diverse portfolio of core products, including specialized treatments for coronary artery disease, thromboembolism, and gastrointestinal infections, directly into Norgine’s extensive European distribution infrastructure. Following the successful closure of the deal, the company was transitioned into a private subsidiary, and its common shares were permanently delisted from the Toronto Stock Exchange and NASDAQ public brokerages.

Visit Website